Assembly Biosciences
Grace Wang, MD, MS, RD, is a seasoned professional in clinical development with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as the Vice President of Clinical Development at Assembly Biosciences, Inc. since May 2021, Grace has previously held various positions at Jazz Pharmaceuticals from 2005 to May 2021, including Executive Director and Director/Senior Director in Clinical Development, as well as roles in medical monitoring and drug safety. Grace's career began at Clinimetrics, where a focus on drug safety was established from 2004 to 2005.
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.